Multiple sclerosis: diagnosis and the management of acute relapses
暂无分享,去创建一个
A J Thompson | A. Thompson | A. Thompson | S. Leary | S M Leary | B Porter | B. Porter
[1] John Noseworthy,et al. Clinical implications of benign multiple sclerosis: A 20‐year population‐based follow‐up study , 2004, Annals of neurology.
[2] D. Mohr,et al. Association between stressful life events and exacerbation in multiple sclerosis: a meta-analysis , 2004, BMJ : British Medical Journal.
[3] F. Lublin,et al. Effect of relapses on development of residual deficit in multiple sclerosis , 2003, Neurology.
[4] A. Thompson,et al. Diagnosis of MS: a comparison of three different clinical settings , 2003, Multiple sclerosis.
[5] Alan J. Thompson,et al. Does neurorehabilitation have a role in relapsing-remitting multiple sclerosis? , 2003, Journal of Neurology.
[6] W. Hop,et al. Self reported stressful life events and exacerbations in multiple sclerosis:prospective study , 2003, BMJ : British Medical Journal.
[7] G. Baker,et al. A randomised controlled trial comparing rehabilitation against standard therapy in multiple sclerosis patients receiving intravenous steroid treatment , 2003, Journal of neurology, neurosurgery, and psychiatry.
[8] K. Lorig,et al. Self-management education: History, definition, outcomes, and mechanisms , 2003, Annals of behavioral medicine : a publication of the Society of Behavioral Medicine.
[9] H. Hartung,et al. Current disease-modifying therapies in multiple sclerosis. , 2003, Seminars in neurology.
[10] D. Matchar,et al. Immunization and MS: A summary of published evidence and recommendations , 2002, Neurology.
[11] W. Hop,et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. , 2002, Brain : a journal of neurology.
[12] A J Thompson,et al. SYMPTOMATIC MANAGEMENT AND REHABILITATION IN MULTIPLE SCLEROSIS , 2001, Journal of neurology, neurosurgery, and psychiatry.
[13] R. Gold,et al. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders , 2001, Journal of Neuroimmunology.
[14] A. Compston,et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis , 2001, Annals of neurology.
[15] S Suissa,et al. Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. , 2001, The New England journal of medicine.
[16] G. Ebers. The natural history of multiple sclerosis , 2000, Neurological Sciences.
[17] D. Goodkin,et al. Psychological stress and the subsequent appearance of new brain MRI lesions in MS , 2000, Neurology.
[18] S. Bernasconi,et al. Long-Term Results with Growth Hormone Therapy in Idiopathic Hypopituitarism , 2000, Hormone Research in Paediatrics.
[19] A J Thompson,et al. Diagnostic criteria for primary progressive multiple sclerosis: A position paper , 2000, Annals of neurology.
[20] B. Weinshenker,et al. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease , 1999, Annals of neurology.
[21] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation. , 1999, Brain : a journal of neurology.
[22] E. Waubant,et al. Multiple sclerosis that is progressive from the time of onset: clinical characteristics and progression of disability. , 1999, Archives of neurology.
[23] D. Goodin,et al. The relationship of MS to physical trauma and psychological stress , 1999, Neurology.
[24] J. Baskerville,et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. , 1999, Brain : a journal of neurology.
[25] F. Barkhof,et al. Primary and transitional progressive MS , 1999, Neurology.
[26] W. Koopman,et al. The journey to multiple sclerosis: a qualitative study. , 1999, The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses.
[27] M. Hutchinson,et al. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. , 1999, The New England journal of medicine.
[28] D. Luscombe,et al. Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom , 1998, Journal of neurology, neurosurgery, and psychiatry.
[29] P. Coyte,et al. Cost Analysis of Methylprednisolone Treatment of Multiple Sclerosis Patients , 1998, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[30] M. Hutchinson,et al. Rate of Pregnancy-Related Relapse in Multiple Sclerosis , 1998 .
[31] G. McDonnell,et al. Clinical study of primary progressive multiple sclerosis in Northern Ireland, UK , 1998, Journal of neurology, neurosurgery, and psychiatry.
[32] S. Farmer,et al. Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis , 1997, The Lancet.
[33] R. Knobler,et al. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis , 1997, Neurology.
[34] S. Reingold,et al. Defining the clinical course of multiple sclerosis , 1996, Neurology.
[35] R. Beck. The optic neuritis treatment trial: three-year follow-up results. , 1996, Archives of ophthalmology.
[36] M. Stewart. Effective physician-patient communication and health outcomes: a review. , 1995, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[37] R. Beck. The Optic Neuritis Treatment Trial: Three-Year Follow-up Results , 1995 .
[38] R. Beck,et al. The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group. , 1993, The New England journal of medicine.
[39] M. Lawden,et al. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. , 1993, Journal of neurology, neurosurgery, and psychiatry.
[40] T. Bergström,et al. Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study , 1993, Journal of Neurology.
[41] A. Sadovnick,et al. Epidemiology of Multiple Sclerosis: A Critical Overview , 1993, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.
[42] O. Andersen,et al. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. , 1993, Brain : a journal of neurology.
[43] D. Paty,et al. Life expectancy in patients attending multiple sclerosis clinics , 1992, Neurology.
[44] I. Moseley,et al. Acute disseminated encephalomyelitis , 2016, Neurology.
[45] C. Kennard,et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS , 1989, Neurology.
[46] B Bass,et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. , 1989, Brain : a journal of neurology.
[47] P. Newman,et al. Methylprednisolone therapy in multiple sclerosis: a profile of adverse effects. , 1988, Journal of neurology, neurosurgery, and psychiatry.
[48] R. Newcombe,et al. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects. , 1987, Journal of neurology, neurosurgery, and psychiatry.
[49] A. Alpérovitch,et al. CLINICAL VIRAL INFECTIONS AND MULTIPLE SCLEROSIS , 1985, The Lancet.
[50] G. Dean,et al. TO TELL OR NOT TO TELL THE DIAGNOSIS OF MULTIPLE SCLEROSIS , 1985, The Lancet.
[51] D. Dick,et al. Intravenous methylprednisolone for multiple sclerosis in relapse. , 1985, Journal of neurology, neurosurgery, and psychiatry.
[52] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[53] C. Kennard,et al. Treatment of acute exacerbations of multiple sclerosis with intravenous methyl-prednisolone. , 1982, Journal of neurology, neurosurgery, and psychiatry.
[54] J. Kurtzke,et al. On the Risk of Multiple Sclerosis According to Age at Immigration to South Africa* , 1971, British medical journal.
[55] F. Mcdowell,et al. PROBLEMS OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS: REPORT BY THE PANEL ON THE EVALUATION OF EXPERIMENTAL TRIALS OF THERAPY IN MULTIPLE SCLEROSIS , 1965, Annals of the New York Academy of Sciences.
[56] Alastair Compston,et al. McAlpine's Multiple Sclerosis , 2005 .
[57] Alan J. Thompson,et al. Developing a measure of patients' experiences of relapse management in multiple sclerosis. , 2003 .
[58] O. Khan,et al. Comparative Assessment of Immunomodulating Therapies for Relapsing-Remitting Multiple Sclerosis , 2002, CNS drugs.
[59] M. Filippi,et al. Primary Progressive Multiple Sclerosis , 2002, Topics in Neuroscience.
[60] Specialist nursing in MS - the way forward: key elements for developing MS specialist nurse services in the UK. , 2001, Nursing management.
[61] C. Poser. The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. , 2000, Neurology.
[62] A. Thompson,et al. A clinical and laboratory study of benign multiple sclerosis. , 1986, The Quarterly journal of medicine.